Evidence map›Paper›PMID 35484614›Full record

ArticleBMC cancer2022

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).

Inderdeep Dhaliwal, Shayan Kassirian, Michael A Mitchell, Mehdi Qiabi, Andrew Warner, Alexander V Louie, Harvey H Wong, Christine M McDonald, Jason Rajchgot, David A Palma

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04852588 (Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04852588 narecruitingnot on this map

Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer (NSCLC) Being Treated With Stereotactic Ablative Radiotherapy (ENDO-SABR)

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2021 to 2025Enrolled29ConditionsNon-Small Cell Lung CancerArmsEndobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA), Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Inderdeep DhaliwalDivision of Respirology, Department of Medicine, London Health Sciences Centre, Western University, London, Ontario, Canada. Inderdeep.Dhaliwal@lhsc.on.ca.ORCID http://orcid.org/0000-0003-1795-3855
Shayan KassirianDivision of Respirology, Department of Medicine, London Health Sciences Centre, Western University, London, Ontario, Canada.
Michael A MitchellDivision of Respirology, Department of Medicine, London Health Sciences Centre, Western University, London, Ontario, Canada.
Mehdi QiabiDivision of Thoracic Surgery, Department of Surgery, London Health Sciences Centre, Western University, London, Ontario, Canada.
Andrew WarnerDivision of Radiation Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, Ontario, Canada.
Alexander V LouieDivision of Radiation Oncology, Department of Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Harvey H WongDivision of Respirology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Christine M McDonaldDivision of Respirology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Jason RajchgotDivision of Respirology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
David A PalmaDivision of Radiation Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, Ontario, Canada.
Western University · CASunnybrook Health Science Centre · CA

Funding

Academic Medical Organization of Southwestern Ontario INN21-009
6 · The paper itself

Abstract

backgroundResearch in treatment of non-small cell lung cancer (NSCLC) has shown promising results with stereotactic ablative radiotherapy (SABR) of oligometastatic disease, wherein distant disease may be limited to one or a few distant organs by host factors. Traditionally, PET/CT has been used in detecting metastatic disease and avoiding futile surgical intervention, however, sensitivity and specificity is limited to only 81 and 79%, respectively. Mediastinal staging still identifies occult nodal disease in up to 20% of NSCLC patients initially thought to be operative candidates. Endobronchial ultrasound and transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive tool for the staging and diagnosis of thoracic malignancy. When EBUS is combined with endoscopic ultrasound using the same bronchoscope (EUS-B), the diagnostic sensitivity and negative predictive value increase to 84 and 97%, respectively. Endoscopic staging in patients with advanced disease has never been studied, but may inform treatment if a curative SABR approach is being taken.

methodsThis is a multi-centre, prospective, cohort study with two-stage design. In the first stage, 10 patients with oligometastatic NSCLC (lung tumour ± hilar/mediastinal lymphadenopathy) with up to 5 synchronous metastases will be enrolled An additional 19 patients will be enrolled in the second stage if rate of treatment change is greater than 10% in the first stage. Patients will be subject to EBUS or combined modality EBUS/EUS-B to assess bilateral lymph node stations using a N3 to N2 to N1 progression. Primary endpoint is defined as the rate of change to treatment plan including change from SABR to conventional dose radiation, change in mediastinal radiation field, and change from curative to palliative intent treatment. DISCUSSION: If a curative approach with SABR for oligometastatic disease is being explored, invasive mediastinal staging may guide treatment and prognosis. This study will provide insight into the use of endoscopic mediastinal staging in determining changes in treatment plan of NSCLC. Results will inform the design of future phase II trials.

trial registrationClinicaltrials.gov identifier NCT04852588. Date of registration: April 19, 2021. PROTOCOL VERSION: 1.1 on December 9, 2021.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCohort StudiesHumansLymphatic MetastasisNeoplasm StagingPositron Emission Tomography Computed TomographyProspective StudiesEndobronchial ultrasound (EBUS)Endoscopic ultrasound (EUS)Non-small cell lung cancer (NSCLC)Oligometastatic diseaseStereotactic ablative radiotherapy (SABR)

Identifiers

PMID35484614
PMCPMC9047351
OpenAlexW4225011859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.